Biogen Net Worth
Biogen Net Worth Breakdown | BIIB |
Biogen Net Worth Analysis
Biogen's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Biogen's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Biogen's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Biogen's net worth analysis. One common approach is to calculate Biogen's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Biogen's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Biogen's net worth. This approach calculates the present value of Biogen's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Biogen's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Biogen's net worth. This involves comparing Biogen's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Biogen's net worth relative to its peers.
Enterprise Value |
|
To determine if Biogen is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biogen's net worth research are outlined below:
| Biogen Inc generated a negative expected return over the last 90 days | |
| Biogen Inc has a poor financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from insidermonkey.com: Biogen Inc. Among the Best Genomics Stocks to Buy Right Now |
Biogen Quarterly Good Will |
|
Biogen uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Biogen Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biogen's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 23rd of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Biogen's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biogen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biogen Inc backward and forwards among themselves. Biogen's institutional investor refers to the entity that pools money to purchase Biogen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Beutel, Goodman & Company Ltd. | 2024-09-30 | 1.7 M | Legal & General Group Plc | 2024-06-30 | 1.5 M | Clearbridge Advisors, Llc | 2024-06-30 | 1.5 M | Ameriprise Financial Inc | 2024-06-30 | 1.5 M | Goldman Sachs Group Inc | 2024-06-30 | 1.4 M | Northern Trust Corp | 2024-09-30 | 1.4 M | Amvescap Plc. | 2024-06-30 | 1.3 M | Bank Of New York Mellon Corp | 2024-06-30 | 1.2 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 1.2 M | Vanguard Group Inc | 2024-09-30 | 16.7 M | Primecap Management Company | 2024-09-30 | 16.3 M |
Follow Biogen's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 22.73 B.Market Cap |
|
Project Biogen's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.09 | 0.08 | |
| Return On Capital Employed | 0.06 | 0.08 | |
| Return On Assets | 0.04 | 0.06 | |
| Return On Equity | 0.08 | 0.10 |
When accessing Biogen's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Biogen's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Biogen's profitability and make more informed investment decisions.
Please note, the presentation of Biogen's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biogen's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biogen's management manipulating its earnings.
Evaluate Biogen's management efficiency
Biogen Inc has return on total asset (ROA) of 0.0499 % which means that it generated a profit of $0.0499 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1047 %, meaning that it created $0.1047 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities. At present, Biogen's Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.06, whereas Return On Tangible Assets are forecasted to decline to 0.08. At present, Biogen's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 21 B, whereas Non Currrent Assets Other are forecasted to decline to about 270.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 102.28 | 107.39 | |
| Tangible Book Value Per Share | 1.50 | 1.43 | |
| Enterprise Value Over EBITDA | 18.40 | 19.32 | |
| Price Book Value Ratio | 2.53 | 2.40 | |
| Enterprise Value Multiple | 18.40 | 19.32 | |
| Price Fair Value | 2.53 | 2.40 | |
| Enterprise Value | 6.4 B | 4.2 B |
The operational strategies employed by Biogen management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 2.8728 | Revenue 9.6 B | Quarterly Revenue Growth (0.03) | Revenue Per Share 66.122 | Return On Equity 0.1047 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biogen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biogen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biogen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Singhal Priya over two months ago Disposition of 1668 shares by Singhal Priya of Biogen subject to Rule 16b-3 | ||
Singhal Priya over six months ago Disposition of tradable shares by Singhal Priya of Biogen at 213.09 subject to Rule 16b-3 | ||
Ginger Gregory over six months ago Disposition of 634 shares by Ginger Gregory of Biogen at 240.98 subject to Rule 16b-3 | ||
Douglas Williams over a year ago Sale by Douglas Williams of 916 shares of Biogen |
Biogen Corporate Filings
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 7th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 30th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 16th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Biogen Earnings per Share Projection vs Actual
Biogen Corporate Executives
Elected by the shareholders, the Biogen's board of directors comprises two types of representatives: Biogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biogen. The board's role is to monitor Biogen's management team and ensure that shareholders' interests are well served. Biogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael CPA | Executive CFO | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.02) | Earnings Share 11.07 | Revenue Per Share 66.122 | Quarterly Revenue Growth (0.03) | Return On Assets 0.0499 |
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.